香雪制药索赔征集中，两类投资者可索赔

Group 1 - The core issue involves Xiangxue Pharmaceutical facing administrative penalties totaling 20.65 million yuan due to related party fund occupation and five years of financial fraud [1][2][3] - The company was found to have falsely reported profits in its 2019 annual report, inflating profits by 53.83 million yuan, which accounted for 45.98% of the total disclosed profit for that year [3] - The company failed to disclose losses from the demolition of five villas in December 2019, leading to significant omissions in its financial statements from 2016 to 2020 [3] Group 2 - Two categories of investors are eligible for compensation: those who bought shares between May 20, 2020, and April 29, 2024, and sold or still hold them at a loss after April 30, 2024, and those who bought shares between March 25, 2017, and September 30, 2024, and sold or still hold them at a loss after October 1, 2024 [4] - The legal actions are being supported by the recent regulatory penalties, which will serve as strong evidence in the upcoming investor compensation lawsuits [4]